by Laurie Erickson.
Cell Therapy Ltd, now known as Celixir, announced positive phase 2 clinical trial results of Tendoncel®, a topical regenerative treatment for chronic tendon injury.
The press release quoted Dr. Sabena Sultan, Director of Research and Development, of Cell Therapy Ltd:
“Patients using the non-invasive Tendoncel® topical gel for 21 days experienced a clinically relevant and statistically significant improvement in their tendon injury. Reporting an average improvement of 70% on the DASH disability scale and 74% improvement on the PRTEE scale, Tendoncel’s results exceed those expected of injectable treatments and have the advantage of painless topical application.”
Tendoncel contains platelet growth factors, including PDGF-BB, VEGF, PDGF-AA, thrombospondin and angiopoietin.